Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like D*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000216	Deciphera Pharmaceuticals, LLC	03/31/2023	73207010130	Qinlock Oral Tablet 50 MG, 90 Each, Bottle	Brand	FDA	01/01/2023	1494.00	37800.00	12/30/2040	Single Source Drug	None	1	The establishment of price and associated price changes may take into consideration a number of factors such as current market dynamics, competitive environment, the clinical and economic value of therapy, therapeutic category, payer environment, government rebates, patient support, overall research and development costs, as well as business operational continuation needs. In our commitment to patients and ensuring patient access, we have a patient support program that provides reimbursement and financial assistance programs for eligible patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000216	Deciphera Pharmaceuticals, LLC	04/29/2024	73207010130	Qinlock Oral Tablet 50 MG, 90 Each, Bottle	Brand	FDA	07/01/2023	1305.00	39105.00	10/06/2042	Single Source Drug	None	None	The establishment of price and associated price changes may take into consideration a number of factors such as current market dynamics, competitive environment, the clinical and economic value of therapy, therapeutic category, payer environment, government rebates, patient support, overall research and development costs, as well as business operational continuation needs. In our commitment to patients and ensuring patient access, we have a patient support program that provides reimbursement and financial assistance programs for eligible patients.	None	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=770	None
Rx0000492	Dynavax Technologies Corporation	03/31/2023	43528000305	HEPLISAV-B [Hepatitis B Vaccine (Recombinant)] Adjuvanted 20 MCG / 0.5 ML PFS Injection, Solution 5 SYRINGE in 1 CARTON (43528-003-05) / .5 mL in 1 SYRINGE (43528-003-01)	Brand	FDA	03/01/2023	36.00	703.00	04/16/2032	Single Source Drug	327131	None	Supply chain cost impacted by pandemic and inflation rate	None	No changes or improvements caused the increase.	None	None	None	None	None	None	None	None	None	None	None	None